Schoenfeld, Ryan C.; Bourdet, David L.; Brameld, Ken A.; Chin, Elbert; de Vicente, Javier; Fung, Amy; Harris, Seth F.; Lee, Eun K.; Le Pogam, Sophie; Leveque, Vincent; Li, Jim; Lui, Alfred S.-T.; Najera, Isabel; Rajyaguru, Sonal; Sangi, Michael; Steiner, Sandra; Talamas, Francisco X.; Taygerly, Joshua P.; Zhao, Junping published the artcile< Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B>, Application In Synthesis of 112-63-0, the main research area is hepatitis C virus NS5B nonnucleoside inhibitor preparation SAR.
Hepatitis C virus (HCV) is a major global public health problem. While the current standard of care, a direct-acting antiviral (DAA) protease inhibitor taken in combination with pegylated interferon and ribavirin, represents a major advancement in recent years, an unmet medical need still exists for treatment modalities that improve upon both efficacy and tolerability. Toward those ends, much effort has continued to focus on the discovery of new DAAs, with the ultimate goal to provide interferon-free combinations. The RNA-dependent RNA polymerase enzyme NS5B represents one such DAA therapeutic target for inhibition that has attracted much interest over the past decade. Herein, we report the discovery and optimization of a novel series of inhibitors of HCV NS5B, through the use of structure-based design applied to a fragment-derived starting point. Issues of potency, pharmacokinetics, and early safety were addressed to provide a clin. candidate in fluoropyridone (I).
Journal of Medicinal Chemistry published new progress about Antiviral agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application In Synthesis of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics